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Abstract
Background: The role of renal lipoprotein lipase (LPL) per se in kidney diseases is still controversial and obscure.
The purpose of this study was to observe the preventive effects of Ibrolipim, a LPL activator, on lipid accumulation
and LPL expression in the kidneys of minipigs fed a high-sucrose and high-fat diet (HSFD).
Methods: Male Chinese Bama minipigs were fed a control diet or HSFD with or without 0.1 g/kg/day Ibrolipim for
5 months. Body weight, plasma glucose, insulin, lipids, LPL activity, and urinary microalbumin were measured. Renal
tissue was obtained for detecting LPL activity and contents of triglyceride and cholesterol, observing the renal lipid
accumulation by Oil Red O staining, and examining the mRNA and protein expression of LPL by real time PCR,
Western Blot and immunohistochemistry.
Results: Feeding HSFD to minipigs caused weight gain, hyperglycemia, hyperinsulinemia, hyperlipidemia and
microalbuminuria. HSFD increased plasma LPL activity while it decreased the mRNA and protein expression and
activity of LPL in the kidney. The increases in renal triglyceride and cholesterol contents were associated with the
decrease in renal LPL activity of HSFD-fed minipigs. In contrast, supplementing Ibrolipim into HSFD lowered body
weight, plasma glucose, insulin, triglyceride and urinary albumin concentrations while it increased plasma total
cholesterol and HDL-C. Ibrolipim suppressed the renal accumulation of triglyceride and cholesterol, and stimulated
the diet-induced down-regulation of LPL expression and activity in the kidney.
Conclusions: Ibrolipim exerts renoprotective and hypolipidemic effects via the increase in renal LPL activity and
expression, and thus the increased expression and activity of renal LPL play a vital role in suppressing renal lipid
accumulation and ameliorating proteinuria in diet-induced diabetic minipigs.
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Introduction
It is now increasingly accepted that abnormal lipid
metabolism and renal accumulation of lipids play an
important role in the pathogenesis of diabetic nephropa-
thy (DN) [1-3]. Numerous experimental studies have
shown the accumulation of triglyceride and cholesterol
in the kidney of animal models fed by a diet rich in
cholesterol and (or) saturated fat and the role of dyslipi-
demia in promoting kidney damage [4-6]. Our recent
works have suggested that feeding high-fat/high-
sucrose/high-cholesterol diet to minipigs induces insulin
resistance [7,8], moderate glomerulosclerosis and early-
stage DN [8]. Understanding the mechanisms whereby
lipids initiate and augment DN is an important unre-
solved question.
Lipoprotein lipase (EC 3.1.1.34; LPL) plays a central
role in lipid metabolism and transports by catalyzing the
hydrolysis of the triglyceride (TG) component of circu-
lating chylomicrons (CM) and very-low-density
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any medium, provided the original work is properly cited.lipoproteins (VLDL) to provide non-esterified fatty acids
and 2-monoacylglycerol for tissue utilization [9]. Con-
sidering tissue-specific regulation and effects of LPL in
lipid metabolism [10], the question arises whether LPL
is involved in the mechanism of DN. LPL is expressed
in mesangial and/or tubular epithelial cells, and localizes
to the endothelial cells as in the blood vessels [11,12].
LPL enhances VLDL binding to glomerular mesangial
cells and induces proliferation and platelet-derived
growth factor (PDGF) expression independent of LPL’s
familiar role in triglyceride hydrolysis [13]. Contradicto-
rily, Li et al [14] find that VLDL-induced triglyceride
accumulation in human mesangial cells is mainly
mediated by the enzymolysis action of LPL. On the con-
trary, there are many reports that LPL expression and
activity in the heart, skeletal muscle, and adipose tissues
are suppressed in humans and experimental animals
with kidney disease [15-18]. In any case, these conflict-
ing results suggest that LPL may be important in med-
iating the initiation and/or progression of renal disease.
In view of the strong connection between LPL and kid-
ney disease, however, it is surprising that there are few
direct studies on the role of renal LPL. It is unknown,
up to now, whether changing the expression of LPL in
kidney per se influences renal lipid metabolism and con-
tributes to the progression of DN in vivo.
I b r o l i p i m( N O - 1 8 8 6 )i san o v e lc o m p o u n dt h a th a s
been reported to increase LPL activity and mass in post-
heparin plasma and LPL mRNA and activity in adipose
tissue, myocardium and skeletal muscle, resulting in a
reduction of plasma TG with concomitant elevation of
high-density lipoprotein cholesterol (HDL-C) in rats
[19-21]. Furthermore, Ibrolipim decreases visceral and
subcutaneous fat accumulation and ectopic lipid deposi-
tion in the heart, skeletal muscle, liver and pancreas in
diet-induced diabetic animal models [7,22,23]. In rat
model of nephrotic syndrome induced by adriamycin
and a high-protein diet, Ibrolipim reduces plasma creati-
nine (Cr), blood urea nitrogen and proteinuria, and
ameliorates tubulointerstitial lesions [24]. However, the
mechanisms responsible for the renoprotective effect of
Ibrolipim in nephrosis are not fully understood. More-
over, whether Ibrolipim affects the expression of LPL
and lipid accumulation in kidney is still unknown.
The purposes of the present study, therefore, are to
examine (a) whether there is LPL expression in the kid-
ney of Chinese Bama minipigs, (b) whether the high-
sucrose and high-fat diet causes renal lipid accumulation
and influences renal LPL expression, (c) whether admin-
istration of Ibrolipim can suppress diet-induced lipid
accumulation and improve renal injury through chan-
ging renal LPL expression, and (d) whether LPL plays
an important role in the pathogenesis of DN.
Materials and methods
Materials
Ibrolipim (NO-1886), 4-diethoxyphosphorylmethyl-N-(4-
bromo-2-cyanophenyl) benzamide (CAS 133208-93-2),
in powder form was synthesized in the New Drug
Research Laboratory of Otsuka Pharmaceutical Factory
Inc. (Tokushima, Japan). Antibody against LPL was pur-
chased from Boster Biotech, Inc. (Wuhan, China).
Immunohistochemical kits were used from the EliVi-
sion™ plus HRP System (Maixin Biotech Inc., Fuzhou,
China). All other chemicals used were high-grade com-
mercially available products.
Animals
Fifteen male Chinese Bama miniature pigs, 3 to 4
months, were obtained from the Laboratory Animal Cen-
ter of the Third Military Medical University (Chongqing,
China). They were housed in single pens under con-
trolled conditions (temperature of 20 ± 2°C and relative
humidity between 30% to 70%) and randomized into
three groups with similar body weight: n = 5 in the nor-
mal control diet (CD) group; n = 5 in the high sucrose
and fat diet (HSFD) group; n = 5 in the HSFD supple-
mented with 0.1 g/kg body weight/day Ibrolipim (HSFD
+Ibrolipim) group. The HSFD used in this study was 51%
normal swine diet supplemented with 37% sucrose, 10%
lard, and 2% cholesterol [8]. The amount of daily fodder
was 4% weight of minipigs which were fed three times a
day. Water was available ad libitum.B o d yw e i g h t sw e r e
recorded every month, and the study period was 5
months. All experiments were performed according to
the guidelines of the Animal Ethics Committee of the
University of South China (No. 2005-016).
Biochemical analysis of plasma and urine
Fasting blood samples were collected from the orbital
sinus for plasma parameters at the end of each month.
Glucose, TG, total cholesterol (TC) and HDL-C were
measured by commercial enzymatic method kits (Rong-
sheng Biotech Inc., Shanghai, China). Insulin was
assayed by a radioimmunoassay kit (China Institute of
Atomic Research, Beijing, China). Homeostatic model
assessment (HOMA) as the estimate of insulin resis-
tance was calculated by the formula: insulin × glucose/
22.5 [25].
An hour after food consumption at the end of 5
th
month, heparin (150 U/kg) was injected into a vein in
one ear, and 10 min later blood was collected from a
vein in the other ear. The plasma was measured for LPL
activity by an immunochemical method described pre-
viously [26] using glycerol tri[l-
14C]oleate as substrate
and selective blocking of hepatic lipase activity with
antiserum to hepatic lipase.
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were used for determination of microalbumin (mALB)
a n dC ra t0 ,2 ,4a n d5m o n t h s .U r i n a r ym A L Bw a s
measured by immunoturbidimetry (Mingdian Biotech
Inc., Shanghai, China). Plasma and urinary Cr were
measured by using the Jaffe method (Jianchen Biotech
Inc., Nanjing, China). The urinary mALB to Cr ratio
was calculated [27].
Biochemical analysis in renal tissue
At the end of the experimental period, the animals were
killed by exsanguination under sodium pentobarbital
anaesthesia. Left kidneys were removed and weighed,
and calculated the kidney weight index (left kidney
weight/body weight ratio, g/kg).
Total lipids were extracted from 1 g of right kidneys
by the method of Bligh and Dyer [28]. Tissue TC and
TG were analyzed by using the enzymatic method with
commercial kits (Rongsheng), and the protein concen-
tration was measured by the BCA Assay Kit (Pierce,
Rockford, IL, USA).
Renal heparin-triggered LPL activity was measured as
reported previously [19,26]. A specimen of kidney was
homogenised in 50 mmol/l NH4Cl buffer (pH 8.5) and
incubated with buffer containing heparin for 60 min at
0°C. The suspension was then centrifuged, and the
supernatant was used to measure LPL activity as
described above.
Quantitative real-time PCR
Total RNA was isolated from right kidneys by TriZol
(Invitrogen, Carlsbad, CA, USA) method. Then, cDNA
was synthesized with Invitrogen SuperScrip preamplifi-
cation system. To investigate the expression of LPL
mRNA, real-time PCR (Rotor-Gene 3000 real-time ana-
lyzer, Corbett Research, Mortlake, Australia) was per-
formed with SYBR Green JumpStart Taq ReadyMix kit
(Sigma-Aldrich, St. Louis, MO, USA). The porcine gene
specific sequence of LPL primer was forward 5’-CGA
AGT ATT GGC ATC CAG AAA C-3’ and reverse 5’-
TTG ATC TCA TAG CCC AAG TTG TT-3’. The rela-
tive amount of LPL mRNA was normalized to the
expression of internal control b-actin in each sample.
T h es e q u e n c eo fb-actin primer was forward 5’-CCT
G T AC G CC A AC A CA G TG C - 3 ’ and reverse 5’-ATA
CTC CTG CTT GCT GAT CC-3’.A l lt h ed a t aw e r e
calculated from triplicate reactions.
Western blotting
Proteins were extracted from left kidneys by using Pro-
tein Extraction Kit (G-Biosciences, St Louis, MO,
USA). After centrifugation, supernatant was obtained
to determine the protein concentration by BCA
method (Pierce). Protein samples (10 μg) were sub-
jected to SDS-PAGE (10% w/v) and then transferred to
nitrocellulose membranes. Membranes were blocked in
5% dried milk in Tris-buffered saline with Tween,
incubated with anti-LPL (1:400 dilution), followed by
horseradish peroxidase-labeled anti-rabbit IgG (1:1000
dilution), and then developed by using the enhanced
chemiluminescence detection kit (Amersham Bios-
ciences, Piscataway, NJ, USA) and XAR sensitive film
(Kodak, Rochester, NY, USA). The signals were quanti-
fied by using the Fluor-S MultiImager system (Bio-Rad
Laboratories, Hercules, CA, USA). The LPL protein
level was assessed by densitometry with b-actin
(Sigma-Aldrich) as a control.
HE staining and Oil Red O staining
Paraffin sections were stained for hematoxylin and eosin
(HE). Frozen sections were used for Oil Red O staining
to determine the renal accumulation of neutral lipid.
The area of lipid droplets, appeared as red spots, was
captured in more than 5 randomly chosen digital photo-
graphs (× 200) made with the Olympus microscope sys-
tem (Tokyo, Japan), and quantitatively measured using
Image-Pro Plus 6.0 software (Media Cybernetics,
Bethesda, MD, USA), and then calculated as a percen-
tage of the field area in each section. The mean area for
each minipig in each group was calculated and com-
pared in a blinded manner by the renal pathologists.
Immunohistochemistry
Kidney sections were deparaffinized, hydrated and then
preincubated with 0.1% trypsin for 30 min at room tem-
perature. After quenching the endogenous peroxidase by
immersion in 3% hydrogen peroxide for 10 min, sections
were incubated at 4°C overnight with polyclonal antibo-
dies against LPL diluted to 1:100, then subsequently
incubated with polymerized HRP-labeled goat anti-rab-
bit IgG for 1 h at 4°C. The antigen was visualized with
diaminobenzidine and counterstained with hematoxylin.
Negative controls were included with substitution of the
primary antibodies with 10% non-immune goat serum.
Statistical analysis
Results are expressed as mean ± SD by using the SPSS
version 17 software. The mALB/Cr ratio was log-trans-
formed to approximate a normal distribution. Compari-
sons among the three groups were analyzed for
statistical significance by using one-way analysis of var-
iance, followed by LSD-t test for multiple comparisons.
Statistical analysis for histological study was performed
by using a nonparametric Mann-Whitney test. Correla-
tion analysis was performed using Pearson’st e s t .P
values less than 0.05 were considered significant.
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Effects of Ibrolipim on body and kidney weights in
minipigs
The body weights of three groups were linearly ele-
vated with feeding duration. Body weight gain was sig-
nificantly higher in the HSFD group than in the CD
group, whereas it was suppressed in the HSFD+Ibroli-
pim group compared with the HSFD group in the 4th
and 5th months (Table 1). There was no significant
difference in the left kidney weight index among the
three groups (CD, 3.42 ± 0.51 g/kg; HSFD, 2.89 ± 0.71
g/kg and HSFD+Ibrolipim, 3.58 ± 0.47 g/kg, P =
0.199).
Effects of Ibrolipim on plasma parameters in minipigs
As shown in Table 1, plasma glucose, insulin, TG, TC
and HDL-C concentrations were significantly increased
in the HSFD group over the control group with feeding
program. Treatment with Ibrolipim lowered plasma glu-
cose, insulin and TG concentrations to be below those
in the HSFD group. However, administration of
Ibrolipim in the HSFD caused an increase of plasma TC
a n dH D L - C ,e v e nh i g h e rt h a ni nt h eH S F Dg r o u p .T h e
degree of insulin resistance calculated by HOMA was
high in HSFD-fed minipigs after 2 months, and sup-
pressed in the HSFD+Ibrolipim group compared with
the HSFD group.
Effects of Ibrolipim on renal function in minipigs
As shown in Table 2, the urinary mALB/Cr ratio was
significantly increased from the 4th month of HSFD-
feeding compared with that of CD-feeding. Ibrolipim
supplementation to HSFD markedly decreased the ratio
compared with HSFD-feeding. No significant changes
were observed in Cr levels of plasma and urine among
three groups.
Effects of Ibrolipim on renal lipid accumulation in
minipigs
The feeding of HSFD increased the contents of TC and
TG in the renal tissues, and these increases were sup-
pressed by the treatment with Ibrolipim (Table 3).
Table 1 Body weight, fasting plasma glucose and lipid metabolites in Chinese Bama minipigs
Parameters Baseline 1 month 2 months 3 months 4 months 5 months
Body weight (kg)
CD 6.04 ± 1.24 9.22 ± 1.29 10.28 ± 1.51 12.34 ± 1.73 14.35 ± 2.14 16.85 ± 3.74
HSFD 6.04 ± 2.12 8.90 ± 2.68 10.76 ± 2.61 14.18 ± 4.25 18.50 ± 5.31 * 23.55 ± 7.46 **
HSFD+Ibrolipim 6.02 ± 1.10 8.48 ± 1.65 10.08 ± 1.84 13.02 ± 2.50 14.40 ± 2.51
# 16.56 ± 3.83
##
Glucose (mmol/l)
CD 4.71 ± 0.39 4.24 ± 0.90 4.83 ± 0.87 5.24 ± 1.00 4.65 ± 0.71 4.77 ± 0.57
HSFD 5.12 ± 0.84 5.97 ± 0.73 * 6.88 ± 0.57 * 8.89 ± 2.05 ** 9.54 ± 2.12 ** 10.27 ± 2.25 **
HSFD+Ibrolipim 4.78 ± 0.62 4.41 ± 1.45 4.96 ± 1.09
# 5.89 ± 0.50
# 4.85 ± 1.10
## 4.75 ± 0.45
##
Insulin (U/l)
CD 6.97 ± 0.33 7.31 ± 0.94 7.50 ± 0.93 8.68 ± 0.82 7.25 ± 0.80 7.65 ± 1.33
HSFD 7.47 ± 1.16 9.12 ± 1.63 15.12 ± 3.22 * 21.16 ± 5.08 * 24.43 ± 3.55 ** 17.43 ± 3.80 **
HSFD+Ibrolipim 7.65 ± 0.91 8.73 ± 1.52 9.43 ± 0.84
# 10.95 ± 2.95
# 10.30 ± 3.57
## 10.34 ± 2.71
#
Homeostatic model assessment
CD 1.38 ± 0.18 1.54 ± 0.50 1.63 ± 0.47 1.97 ± 0.63 1.51 ± 0.32 1.64 ± 0.45
HSFD 1.59 ± 0.26 2.29 ± 0.39 4.38 ± 1.05 ** 7.04 ± 1.05 ** 10.40 ± 1.75 ** 7.83 ± 1.63 **
HSFD+Ibrolipim 1.56 ± 0.26 1.87 ± 0.56 2.11 ± 0.59
## 2.89 ± 0.51
## 2.16 ± 0.45
## 2.62 ± 0.70
##
Triglyceride (mmol/l)
CD 0.59 ± 0.04 0.59 ± 0.06 0.63 ± 0.10 0.69 ± 0.16 0.71 ± 0.15 0.73 ± 0.13
HSFD 0.59 ± 0.05 0.94 ± 0.07 ** 1.50 ± 0.18 ** 1.87 ± 0.14 ** 2.03 ± 0.42 ** 2.10 ± 0.32 **
HSFD+Ibrolipim 0.58 ± 0.04 0.60 ± 0.01
# 0.78 ± 0.08
## 0.87 ± 0.17
## 1.03 ± 0.25
## 1.10 ± 0.35
##
Total cholesterol (mmol/l)
CD 2.06 ± 0.34 1.99 ± 0.33 2.01 ± 0.35 1.68 ± 0.21 1.82 ± 0.49 2.07 ± 0.46
HSFD 2.31 ± 0.44 6.24 ± 1.77 ** 9.06 ± 1.44 ** 11.20 ± 2.02 ** 15.23 ± 2.00 ** 20.45 ± 2.83 **
HSFD+Ibrolipim 2.29 ± 0.55 8.02 ± 2.15
# 11.99 ± 2.15
# 13.55 ± 3.12
# 16.39 ± 4.23 22.14 ± 4.59
HDL cholesterol (mmol/l)
CD 0.78 ± 0.14 0.76 ± 0.18 0.85 ± 0.17 1.02 ± 0.12 0.81 ± 0.16 0.96 ± 0.29
HSFD 0.89 ± 0.12 1.09 ± 0.18 * 1.37 ± 0.28 * 1.82 ± 0.53 * 2.00 ± 0.39 ** 1.83 ± 0.36 **
HSFD+Ibrolipim 0.79 ± 0.15 1.23 ± 0.21 2.29 ± 0.43
## 2.85 ± 0.47
## 2.92 ± 0.54
## 2.86 ± 0.46
##
Values are means ± SD, n = 5 in each group; * P < 0.05, ** P < 0.01 vs. CD group; # P < 0.05, ## P < 0.01 vs. HSFD group.
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or absent lipid deposits in the kidneys of the CD group
(Figure 1A; the percentage of positive area: 0.15% ±
0.04%) and the HSFD+Ibrolipim group (Figure 1C; 0.42%
± 0.13%, P < 0.001 vs.H S F Dg r o u p ) .O nt h eo t h e rh a n d ,
marked deposition in tubular epithelial cells and small
amounts in glomeruli of Oil Red O-stainable lipid were
observed in HSFD group (Figure 1B; 1.14% ± 0.30%, P <
0.001 vs. CD group). Corresponding to biochemical ana-
lysis of lipid composition, these results strongly indicated
that there were excessive amounts of lipid accumulation
in the kidneys of HSFD pigs, and the accumulation could
be eliminated by treating with Ibrolipim.
Effects of Ibrolipim on plasma and renal LPL activity in
minipigs
Postprandial postheparin plasma LPL activity signifi-
cantly increased in the HSFD group compared with the
CD group, and even more in the HSFD+Ibrolipim group
than the HSFD group (Table 3).
Renal tissue LPL activity decreased 28.57% in the
HSFD group compared with the CD group, and
increased 100% after the treatment with Ibrolipim com-
pared with the HSFD group (Table 3).
Effects of Ibrolipim on renal LPL mRNA and protein
expression in minipigs
Quantitative real-time PCR analysis showed that LPL
mRNA levels decreased 28.81% in the kidney tissues of
the HSFD group compared with the CD group. In con-
trast, it increased 61.51% in the HSFD+Ibrolipim group
compared with the HSFD group (Figure 2).
Western blot analysis showed that the protein expres-
sion of LPL was decreased in the kidneys of HSFD vs.
CD minipigs, and HSFD-induced down-regulation of
LPL was increased by the administration of Ibrolipim
(Figure 3).
Immunohistochemical analysis showed that HSFD
decreased the immunoreactivity of LPL in the glomer-
ular endothelial, parietal epithelial, and tubular epithe-
lial cells compared with the CD group. Ibrolipim
reversed the decrease compared with the HSFD group
(Figure 4).
It was worthy to note that the reduction in LPL pro-
tein expression was accompanied by a parallel reduction
in LPL mRNA of renal tissues for the HSFD group. In
contrast, Ibrolipim stimulated the diet-induced down-
regulation of LPL in the kidney.
Effects of Ibrolipim on renal morphology in minipigs
HE staining clearly revealed glomerular hypertrophy,
mesangial expansion, parietal layer of Bowman’sc a p -
sule thickening, inflammatory cell infiltration, and
dilated tubules within hyaline casts in the HSFD-fed
minipigs (Figure 5B) compared with the control mini-
pigs (Figure 5A). These abnormalities associated with
HSFD feeding were attenuated by Ibrolipim treatment
(Figure 5C).
Table 2 Renal function in Chinese Bama minipigs
Parameters Baseline 2 months 4 months 5 months
Urinary microalbumin/creatinine ratio (mg/g)
CD 12.26 ± 2.54 12.77 ± 3.33 13.52 ± 4.67 12.60 ± 3.27
HSFD 12.73 ± 3.14 14.16 ± 3.53 25.13 ± 4.65 * 48.08 ± 11.77 **
HSFD+Ibrolipim 13.18 ± 3.45 12.66 ± 4.01 17.24 ± 5.63
# 24.14 ± 7.99
##
Plasma creatinine (μmol/l)
CD 28.56 ± 5.54 28.97 ± 7.44 28.81 ± 6.02 29.69 ± 3.81
HSFD 26.67 ± 6.53 27.71 ± 6.36 30.76 ± 8.91 33.38 ± 9.10
HSFD+Ibrolipim 28.77 ± 7.34 30.25 ± 6.17 31.56 ± 7.43 32.19 ± 8.01
Urinary creatinine (mmol/l)
CD 3.77 ± 0.53 4.08 ± 0.84 4.13 ± 1.00 4.43 ± 0.87
HSFD 4.05 ± 0.72 4.20 ± 0.92 4.08 ± 0.76 4.71 ± 0.69
HSFD+Ibrolipim 3.92 ± 0.68 4.17 ± 0.96 4.20 ± 1.01 4.48 ± 0.49
Values are means ± SD, n = 5 in each group; * P < 0.05, ** P < 0.01 vs. CD group; # P < 0.05, ## P < 0.01 vs. HSFD group.
Table 3 Renal lipid contents, and renal and plasma LPL activities in Chinese Bama minipigs
Groups Renal triglyceride content
(mg/g protein)
Renal cholesterol content
(mg/g protein)
Renal lipoprotein lipase activity
(U/g protein)
Plasma lipoprotein lipase
activity (U/ml)
CD 7.17 ± 1.53 7.49 ± 1.92 0.07 ± 0.01 7.34 ± 1.72
HSFD 15.99 ± 2.59 ** 18.69 ± 3.99 ** 0.05 ± 0.01 * 31.88 ± 8.14 **
HSFD
+Ibrolipim
7.92 ± 1.45
## 9.00 ± 2.83
## 0.10 ± 0.01
## 47.55 ± 5.38
##
Values are means ± SD, n = 5 in each group; * P < 0.05, ** P < 0.01 vs. CD group; ## P < 0.01 vs. HSFD group.
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cholesterol and LPL activity in kidneys
As shown in Figure 6, triglyceride content and choles-
terol content were inversely correlated with LPL activity
in kidneys (r = -0.77, P = 0.001; r = -0.71, P = 0.003,
respectively).
Discussion
In our research, HSFD-feeding to minipigs for 5 months
induced weight gain, hyperglycemia, hyperinsulinemia,
insulin resistance, hypertriglyceridemia, hypercholestero-
lemia and microalbuminuria. The diet induced excessive
amounts of lipid deposits in the kidney, as shown by
increased Oil Red O staining and significantly higher
renal contents of triglyceride and cholesterol. We also
found that HSFD resulted in renal morphological
abnormality, which was characterized by glomerular
hypertrophy, mesangial expansion, inflammatory cell
infiltration and dilated tubules within hyaline casts.
Results from our study do confirm those previous find-
i n g sa n ds u p p o r tt h et h e o r yt h a td i e t - i n d u c e dl i p i d
metabolism disorder and excessive renal lipid accumula-
tion are contributing to the development of DN
[3,6,8,29].
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Figure 1 Representative photomicrographs of Oil Red O staining in frozen kidney sections from Chinese Bama minipigs. No apparent
lipid droplets, appeared as red spots, were observed in the control group (1A) and the HSFD+Ibrolipim group (1C). There were marked
deposition in tubular epithelial cells and small amounts in glomeruli of Oil Red O-stainable lipid in the HSFD group (1B) (× 200 magnification).
(1D) The percentage of Oil Red O-positive area was used for comparison (mean ± SD). * P < 0.01 vs. CD group; # P < 0.01 vs. HSFD group.
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Figure 2 The mRNA expression of lipoprotein lipase in the
kidneys of Chinese Bama minipigs performed by real-time PCR.
The relative mRNA levels, normalized to an internal control b-actin,
were calculated according to the formula 2
-ΔCT. Data are the means
± SD, * P < 0.01 vs. CD group; # P < 0.01 vs. HSFD group.
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Page 6 of 10Furthermore, our study has the following novel find-
ings. The first is that the elevation of renal triglyceride
and cholesterol contents is correlated with a significant
reduction in renal LPL activity (Figure 6). This is
accompanied by a parallel reduction in mRNA and
p r o t e i ne x p r e s s i o no fr e n a lLPL. The specific immuno-
localization with anti-LPL antibodies by using
immunohistochemistry is expressed in the glomerular
endothelial, parietal epithelial, and tubular epithelial
cells, where ectopic lipid deposition is observed in
HSFD-fed minipigs with Oil Red O staining. However,
there are conflicting reports that LPL is expressed by
different types of renal cells, and its mRNA, mass and
activity in kidneys vary widely among different species,
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Figure 3 Western blot and densitometric quantification of lipoprotein lipase protein in the kidneys of Chinese Bama minipigs.T h e
expression intensity of LPL protein relative to that of b-actin was calculated for comparison. Data are the means ± SD, * P < 0.01 vs. CD group;
# P < 0.01 vs. HSFD group.
A B C
Figure 4 Representative photomicrographs of immunohistochemical staining for lipoprotein lipase protein in kidney sections from
Chinese Bama minipigs. The positive staining appeared as brown in the glomerular and tubulointerstitial cells of the control group (4A), the
HSFD group (4B) and the HSFD+Ibrolipim group (4C). Original magnification × 200.
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[11,12,30-33]. Mesangial cells, but not epithelial cells,
express LPL mRNA in human and rat [11]. Immunos-
taining for kidney LPL indicates that the enzyme is
present in tubular epithelial cells of mouse and mink
[12] and vascular endothelium of glomeruli in guinea
pig [34]. To our knowledge, the present study is the
first to report that the expression and activity of LPL
are evaluated in the kidney of Chinese Bama minipigs,
a n dd o w n - r e g u l a t e db yH S F Df o r5m o n t h s .
The second novel finding of our study is that HSFD
feeding increases postprandial postheparin plasma LPL
activity while decreases the mRNA and protein expres-
sion and activity of renal LPL. However, the mechanism
f o rt h i sp h e n o m e n o ni sn o tc l e a r .P r e v i o u ss t u d yh a s
shown that plasma LPL activity increases and reaches a
maximum at 6 h after intake of the oral fat load in
humans [35]. Moreover, LPL activity is regulated
according to nutritional state in a tissue-specific manner
[10]. Adipose tissue LPL activity rises rapidly after feed-
ing by a post-transcriptional mechanism in guinea pigs
and mice [36,37]. In SD rats, a high-fat diet differentially
affects LPL activity in muscle and adipose tissue, redu-
cing the former and greatly increasing the latter, which
tends to induce fat storage and insulin resistance [22]. It
is, therefore, speculated that HFSD seems to promote
the release of LPL from peripheral tissues such as adi-
pose tissue to blood.
Several studies have revealed that peripheral catabo-
lism of triglyceride-laden lipoproteins (i.e., CM and
VLDL) is impaired and postheparin LPL activity and
mass are reduced in clinical nephrosis [15,38,39]. In ani-
mal models of kidney disease, significant reduction of
LPL activity, mRNA level or protein mass is observed in
the cardiac muscle, skeletal muscle and adipose tissues
[16-18,33,40,41]. These studies are consistent with an
important role for acquired LPL deficiency in the patho-
genesis of dyslipidemia and renal diseases. In sharp con-
trast, studies in vitro have shown that LPL enhances the
binding of VLDL to mesangial cells via a heparan sul-
fate-dependent mechanism [13], increases cellular trigly-
ceride accumulation via enzymolysis [14], and
stimulates both the proliferation of these cells and the
expression of PDGF [13]. In baby hamster kidney (BHK)
A B C
Figure 5 Representative photomicrographs of HE staining in kidney sections from Chinese Bama minipigs.( 5 A )C o n t r o lg r o u p ;( 5 B )
HSFD group; (5C) HSFD+Ibrolipim group. Original magnification × 200.
Figure 6 Correlations between contents of triglyceride and cholesterol and LPL activity in kidney.
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Page 8 of 10and human embryonal kidney 293 (HEK 293) cells, the
stimulating effect of LPL on HDL3 selective cholesteryl
ester uptake is independent of lipolysis [42]. Above all,
both clinical and experimental studies are still producing
conflicting findings that LPL may have pro-nephrogenic
or anti-nephrogenic effects.
Our minipigs with diet-induced DN exhibits a signifi-
cant LPL deficiency in kidney tissue per se,a n dt h i s
seems to imply that renal LPL have beneficial effects on
lipid metabolism and renal protection. Therefore, LPL
activator might protect the kidney from injury to lipid
accumulation. In fact, losartan improves lipid metabo-
lism abnormality and increases LPL activity in adipose
tissue of rats with renal artery stenosis [43]. Oral admin-
istration of 100 mg/kg Glycyrrhizic acid up-regulates the
LPL mRNA expression in the kidney of high-fat diet
induced obese rats [33].
The third novel finding of the present study is that
LPL selective activator Ibrolipim, given for 5 months
in combination with HSFD, significantly reduces
hyperglycemia, hyperinsulinemia, insulin resistance,
hypertriglyceridemia, microalbuminuria, renal fat accu-
mulation, and improves pathological injury, all consis-
tent with the increase in renal LPL activity and
expression. These existing evidences suggest that the
renoprotective effects of Ibrolipim on suppressing tri-
glyceride and cholesterol accumulation in kidney may
be directly attributable to the activation of the down-
regulation of renal LPL mRNA and protein and activity
induced by HSFD.
Of course, additional mechanisms may be responsible
for the effects of Ibrolipim. Firstly, Ibrolipim reduces
ectopic lipid deposition in the heart, skeletal muscle,
liver and pancreas in diet-induced diabetic animal
model [22,23] through increasing LPL activity in soleus
skeletal muscle and myocardium with an increase in fat
oxidation [22]. Therefore, it is possible that the increase
of renal LPL expression and activity can also lead to an
increase of triglyceride utilization in kidney. Secondly,
Ibrolipim has been proved to be highly effective in
increasing plasma HDL-C through mediating reverse
cholesterol transport from peripheral tissues to the liver
to protect against the excessive accumulation of choles-
terol [44]. Thirdly, Ibrolipim exhibits the significant
inhibitory activity of in vitro mesangial cell proliferation
[45]. Further studies are warranted to determine the
mechanisms of Ibrolipim in the suppression of renal
lipid accumulation and renal disease.
Conclusions
In summary, renal LPL plays a crucial role in the patho-
physiology of lipid metabolism and the pathogenesis of
nephropathy, and activation of renal LPL is renoprotec-
tive in diet-induced DN. However, the fact that our and
others’ studies are still producing conflicting findings
with respect to the role of LPL only suggests that our
understanding of LPL and Ibrolipim are not thorough.
It is undeniable that Ibrolipim, a lipoprotein lipase ago-
nist, has been proved to have potential benefit for pre-
vention and treatment of DN.
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